- Home
- BRN vs INAB Comparison
BRN vs INAB Comparison
Compare BRN & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRN
- INAB
- Stock Information
- Founded
- BRN 1956
- INAB 2016
- Country
- BRN United States
- INAB United States
- Employees
- BRN N/A
- INAB N/A
- Industry
- BRN Oil & Gas Production
- INAB Biotechnology: Pharmaceutical Preparations
- Sector
- BRN Energy
- INAB Health Care
- Exchange
- BRN Nasdaq
- INAB Nasdaq
- Market Cap
- BRN 17.6M
- INAB 18.8M
- IPO Year
- BRN N/A
- INAB 2021
- Fundamental
- Price
- BRN $1.35
- INAB $0.19
- Analyst Decision
- BRN
- INAB Strong Buy
- Analyst Count
- BRN 0
- INAB 2
- Target Price
- BRN N/A
- INAB $3.60
- AVG Volume (30 Days)
- BRN 6.7K
- INAB 726.1K
- Earning Date
- BRN 05-13-2025
- INAB 05-08-2025
- Dividend Yield
- BRN N/A
- INAB N/A
- EPS Growth
- BRN N/A
- INAB N/A
- EPS
- BRN N/A
- INAB N/A
- Revenue
- BRN $20,046,000.00
- INAB N/A
- Revenue This Year
- BRN N/A
- INAB N/A
- Revenue Next Year
- BRN N/A
- INAB N/A
- P/E Ratio
- BRN N/A
- INAB N/A
- Revenue Growth
- BRN N/A
- INAB N/A
- 52 Week Low
- BRN $1.26
- INAB $0.13
- 52 Week High
- BRN $3.20
- INAB $1.74
- Technical
- Relative Strength Index (RSI)
- BRN 37.40
- INAB 52.85
- Support Level
- BRN $1.31
- INAB $0.15
- Resistance Level
- BRN $1.52
- INAB $0.19
- Average True Range (ATR)
- BRN 0.08
- INAB 0.01
- MACD
- BRN -0.00
- INAB 0.01
- Stochastic Oscillator
- BRN 19.05
- INAB 92.30
About BRN Barnwell Industries Inc.
Barnwell Industries Inc is an oil and gas firm. Its areas of operations include acquiring, developing, producing, and selling oil and natural gas. The company acquires and develops crude oil and natural gas assets. The company's operating segment includes Oil and natural gas, Contract drilling, Land investment, and Others. It generates maximum revenue from the Oil and natural gas segment. It operates in two geographical segments the United States, which generates a majority of revenue, and Canada.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.